Epigenomics AG

EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Strategic Partner Abbott Launches Colorectal Cancer Blood Test in Europe and Asia/Pacific

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
-------------------------------------------------------------------------------- 

Licensing Agreements/Molecular diagnostics

21.12.2009

Berlin, December 21, 2009 - Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, informs that its strategic licensing and collaboration partner Abbott launched a molecular diagnostic blood test to aid in the diagnosis of colorectal cancer in Europe and Asia/Pacific. The in vitro diagnostic test is based on Epigenomics´ proprietary biomarker Septin9. Abbott licensed the non-exclusive worldwide rights to Septin9 in September 2007. The in vitro diagnostic test is commercialized by Abbott under the brand name Abbott RealTime mS9 Colorectal Cancer Assay and is optimized for Abbott´s RealTime system m2000. The launch triggers a milestone payment to Epigenomics. Going forward Epigenomics will participate in the commercial success of the mS9 Colorectal Cancer Assay through royalties on product sales as well as certain sales-related milestones. With the launch Epigenomics continues executing its dual business model of non-exclusive licensing and direct commercialization of its cancer molecular diagnostic tests.

End of Ad hoc

Epigenomics legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward- looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale in the United States. The analytical and clinical performance characteristics of any product based on this technology which may be sold at some future time in the U.S. have not been established.

end of announcement                               euro adhoc
-------------------------------------------------------------------------------- 

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade
Original-Content von: Epigenomics AG, übermittelt durch news aktuell

Das könnte Sie auch interessieren: